Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly And AC Immune Partner On A Small Molecule With Potential In Alzheimer's Combinations

Executive Summary

Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.

You may also be interested in...



Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline

Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.

Biopharma Quarterly Dealmaking Statistics, Q4 2018

At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.

Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel